本文报告了20例胰腺癌患者胰腺分泌性胰蛋白酶抑制剂(FSTI),弹性蛋白酶-1.铁蛋白和CEA放射免疫测定的结果,并探讨了它们之间的关系。胰腺癌患者与正常人血清的免疫反应性PSTI水平的差别非常显著,阳性率为14/20。4项指标的血清值之间无显著相关性,在阳性率上也无显著差别。CEA联合PSTI等任一项检测能显著提高阳性率,而四者合用则未能进一步提高阳性率。结果表明,PSTI可能成为胰腺癌 This paper reports the results of pancreatic secretory trypsin inhibitor (FSTI), elastase-1. Ferritin, and CEA radioimmunoassay in 20 pancreatic cancer patients and discusses the relationship between them. The difference in the level of immunoreactive PSTI between pancreatic cancer patients and normal people was very significant, with a positive rate of 14/20. There was no significant correlation between the serum values ​​of the 4 indicators and there was no significant difference in the positive rate. CEA combined with PSTI and other tests can significantly increase the positive rate, while the combined use of the four can not further increase the positive rate. Results show that PSTI may become pancreatic cancer